ES2557199T3 - Procedimiento para la preparación de prasugrel - Google Patents

Procedimiento para la preparación de prasugrel Download PDF

Info

Publication number
ES2557199T3
ES2557199T3 ES12740371.5T ES12740371T ES2557199T3 ES 2557199 T3 ES2557199 T3 ES 2557199T3 ES 12740371 T ES12740371 T ES 12740371T ES 2557199 T3 ES2557199 T3 ES 2557199T3
Authority
ES
Spain
Prior art keywords
prasugrel
formula
compound
base
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12740371.5T
Other languages
English (en)
Spanish (es)
Inventor
Ravindranath Vishnu NEWADKAR
Anil Purushottam Joshi
Samir RAGHUNATH BENDRE
Deepak HEMANT JERE
Pere Dalmases Barjoan
Isabel NAVARRO MUÑOZ
Juan Huguet Clotet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuraxpharm Pharmaceuticals SL
Original Assignee
Laboratorios Lesvi SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Lesvi SL filed Critical Laboratorios Lesvi SL
Application granted granted Critical
Publication of ES2557199T3 publication Critical patent/ES2557199T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ES12740371.5T 2011-07-28 2012-07-30 Procedimiento para la preparación de prasugrel Active ES2557199T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11175721 2011-07-28
EP11175721 2011-07-28
US201161574248P 2011-07-29 2011-07-29
US201161574248P 2011-07-29
EP12150675 2012-01-10
EP12150675 2012-01-10
PCT/EP2012/064852 WO2013014295A1 (en) 2011-07-28 2012-07-30 Process for preparing prasugrel

Publications (1)

Publication Number Publication Date
ES2557199T3 true ES2557199T3 (es) 2016-01-22

Family

ID=47600543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12740371.5T Active ES2557199T3 (es) 2011-07-28 2012-07-30 Procedimiento para la preparación de prasugrel

Country Status (4)

Country Link
EP (2) EP2736509B1 (enExample)
JP (1) JP2014524929A (enExample)
ES (1) ES2557199T3 (enExample)
WO (1) WO2013014295A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085541A (zh) * 2014-05-07 2015-11-25 江苏先声药业有限公司 一种普拉格雷类似物的制备方法
CN104592250B (zh) * 2015-01-15 2016-05-11 新发药业有限公司 一种低成本的普拉格雷的环保制备方法
CN106117240A (zh) * 2016-06-09 2016-11-16 青岛辰达生物科技有限公司 一种制备抗血栓药物普拉格雷的方法
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
WO2018073437A1 (en) 2016-10-21 2018-04-26 Laboratorios Lesvi, Sl Pharmaceutical formulations of prasugrel and processes for the preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR20080021152A (ko) 2000-07-06 2008-03-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
US20100261908A1 (en) * 2007-11-09 2010-10-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel , and its salts and polymorphs
CN101177430A (zh) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
DE602008002820D1 (de) * 2008-04-25 2010-11-11 Sandoz Ag Hydrogensulfat von 2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜpyridin und dessen Zubereitung
CZ2009763A3 (cs) * 2009-11-16 2011-05-25 Zentiva, K. S. Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a jeho nových farmaceuticky prijatelných solí.
KR20140048079A (ko) * 2011-02-01 2014-04-23 교와 핫꼬 기린 가부시키가이샤 축환 복소환 유도체

Also Published As

Publication number Publication date
EP2985023A1 (en) 2016-02-17
JP2014524929A (ja) 2014-09-25
EP2736509A1 (en) 2014-06-04
EP2736509B1 (en) 2015-09-23
WO2013014295A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
ES2525112T3 (es) Procedimiento para la preparación de dabigatran etexilato
ES2564006T3 (es) Preparación de hidrocloruro de nalmefeno a partir de naltrexona
US20080051581A1 (en) Novel process for the manufacture of (+)-(S)-clopidogrel bisulfate form-1
EP2736509B1 (en) Process for preparing prasugrel
CN104130273A (zh) 一种头孢曲松钠的合成方法
CN103304512A (zh) 一种非布索坦的制备方法
ES2557762T3 (es) Proceso para la preparación de ésteres de ácido (5-fluoro-2-metil-3-quinolin-2-ilmetil-indol-1-il)-acético
BR112020011040A2 (pt) processo de preparação de roxadustat e seus intermediários
US20130274284A1 (en) Preparation of prasugrel hydrochloride
US20060047121A1 (en) Novel process for preparation of clopidogrel bisulfate polymorph - Form I
ES2746016T3 (es) Procedimiento para la preparación de cristales de clorhidrato de fingolimod
KR20080055860A (ko) 클로피도그렐 바이설페이트의 제조 방법
CN102532168A (zh) 头孢哌酮酸的合成方法
CN106220648A (zh) 一种叔丁氧羰基头孢卡品酸二异丙胺盐的合成及纯化方法
CN106045898A (zh) 一种吲哚类化合物及其制备方法和用途
WO2011042804A2 (en) An improved process for the preparation of clopidogrel hydrogen sulfate form i
US7396931B2 (en) Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
US7994322B2 (en) Processes for the preparation of different forms of (S)-(+)-clopidogrel besylate
EP0311521B1 (fr) Dérivés des céphalosphorines à pharmacocinétique améliorée, procédé pour leur préparation, compositions pharmaceutiques les contenant et intermédiaire de synthèse
CN103864817B (zh) 一种噻吩并吡啶类化合物的制备方法
CN100575353C (zh) 一种噻吩并四氢吡啶乙酸甲酯化合物的制备方法
ES2901555T3 (es) Proceso de preparación de prasugrel de alta pureza
CN100417653C (zh) 噻吩并四氢吡啶乙酸及其盐的制备方法
EP4201920A1 (en) Method for purifying halogen-containing (meth)acrylate
JP2021511375A (ja) 三環式化合物の結晶形、塩形及びその製造方法